Sublingual Delivery of Frovatriptan: An Indication of Potential Alternative Route

Figure 5

Histopathological characterization of test formulation (F9) with respect to control batch (a) mucosa of ventral surface of tongue exposed to test formulation, (b) mucosa of ventral surface of tongue—control, (c) mucosa of floor of mouth exposed to test formulation, and (d) mucosa of floor of mouth—control.

(a)

(b)

(c)

(d)